semaj83/ctmatch_classification huggingface dataset:
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.115-0.231,  Pneumococcal Infections Male or female between, and including, 6-12 weeks (42 to 90 days) of age at the time of the first vaccination Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol Written informed consent obtained from the parent or guardian of the subject Free of obvious health problems as established by medical history and clinical examination before entering into the study Born after a gestation period between 36 and 42 weeks  Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3 Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases History of allergic disease or reactions likely to be exacerbated by any component of the vaccines History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease Acute disease at the time of enrolment Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical A family history of congenital or hereditary immunodeficiency
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 1.0-18.0,  Sleep Apnea, Obstructive Respiration Disorders year old to 18 years of age, clinical signs or symptoms of obstructive sleep apnea (snoring, witnessed apneas, daytime somnolence, restless sleeping, or cyanosis), abnormal polysomnogram (mild, moderate, or severe OSA) including CO2 measures, failed or refused trial of CPAP, or not recommended by their pulmonologist or primary care doctor  prior laser supraglottoplasty, prior adenoidectomy prior tonsillectomy, stridor with cyanosis or apnea, severe respiratory distress, recurrent pneumonia (x3), Laryngeal cyst, vocal cord (VC) Paralysis, airway vascular malformation, neoplasm, subglottic hemangioma, paradoxical vocal cord (VC) motion, posterior glottic stenosis, glottic webs, discoordinate pharyngolaryngomalacia, or refusal to participate
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.167-4.917,  Severe Pneumonia Age: 2 to 59 months Sex: Both boys and girls Severe pneumonia according to WHO (Severe pneumonia is defined as cough or difficult breathing with lower chest wall in drawing with or without fast breathing which is defined as the respiratory rate ≥ 50 breaths per minute for children aged 2-11 months and ≥ 40 breaths per minute for children aged 12-59 months) Attend the Radda Clinic and ICHSH between 8:00 am to 4:00 pm (Sunday through Saturday) Written informed consent by respective parents/guardians  Very severe and non-severe pneumonia Nosocomial pneumonia History of taking antibiotics for pneumonia within 48 hour prior to enrollment Chronic illnesses like tuberculosis, cystic fibrosis Congenital deformities/anomalies e.g. Down's Syndrome, congenital heart disease Immunodeficiency Trauma/burn Bronchiolitis Bronchial asthma Lives far away from the Radda Clinic and ICHSH (outside 5 km radius from the respective study site)
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Drooling Parkinsons' Disease patients with Sialorrhea for at least 3 months  Patients with non-idiopathic PD parkinsonism Patients previously exposed to botulinum toxins Patients with a history of aspiration pneumonia, moderate/severe choking and/or moderate/severe dysphagia Patients with prior salivary gland surgery
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 2.0-4.917,  Healthy Healthy Age: born within the same calendar quarter as the reference FluMist vaccinee  Children who have evidence of medical conditions that put them at high risk for complications of influenza (e.g., chronic cardiovascular and pulmonary disease) will be excluded from this control group
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Intrathoracic Malignancies Unilateral Vocal Cord Paralysis Patients with UVCP undergoing type I thyroplasty or vocal fold augmentation for rehabilitation of speech and swallowing for the healthy subjects From age 18-85  for the UVCP patients includes the following History of significant psychiatric condition (e.g. schizophrenia, obsessive-compulsive disorder, significant dementia) History of the following neurological conditions: CVA, seizure disorders, demyelinating conditions, systemic neuromuscular disorders, cerebral palsy, Alzheimer's disease History of previous moderate to severe traumatic brain injury History of significant cardiovascular, gastrointestinal or renal disease (e.g. myocardial infarction within the previous 12 months, significant vaso-occlusive disease, severe or advanced asthma, or renal compromise) History of achalasia History of dysphagia, odynophagia, or aphasia unrelated to present illness History of significant claustrophobic reactions Standard contraindications to MR examinations (e.g. implanted stimulators, pregnancy) for the healthy subjects includes the following
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Paralysis American Society of Anesthesiology physical status grade I-II Age 18-80 yr Elective gynecological surgery Supine position  Known or predicted difficult airway Body mass index >35 kg m-2 Risk of aspiration
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.231-999.0,  Rotavirus Severe Gastroenteritis for enrolled subjects and cases  A male or female child born after 1 March 2006 (which corresponds to the date of introduction of Rotarix™ in the EPI) and at least 12 weeks of age Subject admitted to the study hospital for SGE (refer to the glossary) during the study period Onset of SGE <= 14 days prior to admission Laboratory confirmed (i.e. by ELISA at the hospital laboratory) RV positive stool sample at hospital admission or during the first 48 hours of hospitalisation. Note: This criterion is applicable only for cases Written informed consent obtained from the parent or guardian of the subject for controls Admitted for non-GE causes at the same hospital as the case. Note: This criterion is applicable to hospital controls only Living in the same neighbourhood as the case for at least three consecutive months. Note: This criterion is applicable to neighbourhood controls only At least 12 weeks of age and being born within ± 2 weeks from the date of birth of the case. If the list of children born within ± 2 weeks is exhausted, then the range would be extended to ± 4 weeks  for enrolled subjects and cases Subject has previously participated as case or control in this study Hospitalisation is unrelated to GE Onset of SGE > 48 hours after admission to the hospital (nosocomial infections) for controls For hospital controls: Child who has symptoms of GE during current hospitalisation or on the day of interview of his/her parent or guardian For neighbourhood controls: Child who has symptoms of GE on the day of interview of his/her parent or guardian children with the following vaccine preventable diseases: measles, mumps, rubella, diphtheria, pertussis, tetanus, tuberculosis, invasive Haemophilus Influenzae Type B (Hib) infections (meningitis, bacteraemia, septic arthritis, cellulitis, and epiglottitis) and hepatitis B Child has participated in the past as a case or control in this study Child living in the same house as the case. Note: This criterion is applicable to neighbourhood controls only
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Varicella (Chickenpox) Chickenpox Vaccines Male or female child at least one year of age, born on or after July 1 2003 Residence in Germany At least one previous well-child visit to the practice Written informed consent obtained from parents/guardians of the subject as per local requirements Specific criterion for cases Suspected primary varicella disease (i.e. chickenpox) at the time of study entry  Ineligible for varicella vaccination, due to any medical contraindication. These contraindications are History of hypersensitivity to any of the components of the vaccines Congenital or acquired immunodeficiency Treatment with immunosuppressive therapy HIV-infected patients, when CD4 < 25% of total lymphocytes Previous history of chickenpox by physician record or parental report Lack of documented vaccination history (written or computerised practice records or child's vaccination card/booklet)
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.167-1.667,  Haemophilus Influenzae Type b Infants of either sex, aged 16 months / 2 months in good health as determined by: medical history physical examination clinical judgment of the investigator available for all visits scheduled in the study and able to comply with all study regulations written informed consent obtained, from at least one parent or legal guardian  parent or legal guardian is unwilling or unable to give written informed consent to participate in study infants who presented a previous disease potentially related to Haemophilus influenzae type b infants who had household contact and/or intimate exposure in the previous 30 days to an individual with ascertained Haemophilus influenzae type b disease infants who have received any other Haemophilus influenzae type b immunization dose before (for 16-20 months old children who have received a booster vaccination already) premature (before 37th week of gestation) or birth weight less than 2500 g history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or hypersensitivity to any vaccine component fever ≥38.0 °C (axillary body temperature) and/or significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment subjects with any serious chronic disease such as cardiac, neurological, metabolic, hematologic, or neoplastic disease known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder subjects with any neurological disorder, e.g., epilepsy or history of seizure disorder
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-54.0,  Haemophilus Influenzae (NTHI) for Inoculated Volunteers Healthy 18-54 years old (male or female) with no chronic medical conditions with the exception of well-controlled hypertension Availability for study visits over the next 1 month Normal hemoglobin, white blood cell count, creatinine, alanine aminotransferase (ALT), platelet count Signed informed consent form In good health as determined by medical history and physical exam on the screening evaluation [including heart rate 55-100 beats per minute (bpm); blood pressure: systolic 90-140 mm Hg and diastolic 50-90 mm Hg]. If the subject is a well trained athlete by the judgment of the Principal Investigator (PI), heart rate of 40-100 bpm is acceptable Negative urine pregnancy test for women of childbearing potential If the subject is female and of childbearing potential, she agrees to use acceptable contraception and not become pregnant for the duration of the study. (Acceptable contraception includes abstinence, implants, injectables, combined oral contraceptives, effective intrauterine devices, or a vasectomized partner) Negative human immunodeficiency virus (HIV) enzyme linked immunosorbent assay (ELISA) for HIV 1 and 2 or indeterminate Western blot or other assay confirming that the serostatus does not reflect HIV infection, negative hepatitis C and hepatitis B serology or other assay confirming that the serostatus does not reflect active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection Negative urine protein and glucose by dipstick  for Inoculated Volunteers Acute illness within the week prior to inoculation Acute febrile illness (oral temperature greater than or equal to 100.4 degrees Fahrenheit) on the day of inoculation Allergic rhinitis requiring therapy in the past year Treatment for sinusitis, otitis, chronic bronchitis, pneumonia, bronchospasm or asthma in the past 5 years Abnormal gag reflex Active drug or alcohol abuse Smoking tobacco within the past year Average ingestion of more than one alcoholic beverage per day for women or two alcoholic beverages per day for men Splenectomy or disease that results in functional asplenism such as sickle cell diseases
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.5-17.0,  Intubation months of age to 17 years of age (not yet 18) Male or female English or Spanish speaking Normal airway (Mallampati Classification ) American Society of Anesthesiology Physical Status Classification I or II Elective surgical procedure expected to last at least 45 minutes in length Written informed consent/assent for participation given by the parent legal guardian and subject (if applicable)  < 6 months of age, > 17 years of age Difficult airway (Mallampati Classification) History of previous difficult intubation, suspected abnormal airway: *micrognathia facial trauma airway tumor epiglottitis retropharyngeal abscess foreign body, etc Scheduled for non-elective, emergent OR procedure Parent, legal guardian, or subject is unavailable or unwilling to consent for study participation
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.5-3.0,  Croup Written informed consent obtained by parents/legal representative prior to any study-related procedures Male or female subject aged between 6 months and 3 years referring to ER with acute onset barky cough, stridor, hoarseness, and respiratory distress Children with a diagnosis of moderate croup (Westley score 3-8)  Symptoms or signs of any other cause of stridor Previous acute angioneurotic oedema Children with diagnosis of severe croup (Wesley score >8) History of congenital or acquired stridor, diagnosis of epiglottitis, chronic pulmonary disease, asthma, severe systemic disease, exposure to chickenpox virus within the previous 21 days, or known immune dysfunction Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study Treatment with oral or parenteral corticosteroids within the previous 2 weeks; Treatment with epinephrine for respiratory distress before enrollment Previous visit to an emergency room department due to croup during this episode of the disease Inability of the parent to understand the nature and scope of the study or the possible benefits or unwanted effects of the study treatments Enrollment in another clinical trial in the previous 4 weeks or subject already admitted in this study Lack of a telephone at home
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Abscess, Peritonsillar clinical existence of a PLA (phlegmon), validated by a senior ENT, usually (but not necessarily) following a request by an emergency. The visible appearance to the merits throat must justify puncture. Cases will be included whether or not they had consulted for a "sore throat" in the 10 days preceding the date of diagnosis  Neoplastic disease of the throat, scalable Hematologic with tonsillar localization History of tonsillectomy
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Dysphagia Dysphonia Patients undergoing revision anterior cervical spine surgery  Primary pathology of the upper aero-digestive tract other than mild chronic pharyngitis, pre-existing vocal cord paralysis
Patient description: A 5-year-old boy presents to the emergency department with complaints of progressively worsening dysphagia, drooling, fever and vocal changes. He is toxic-appearing, and leans forward while sitting on his mother's lap. He is drooling and speaks with a muffled "hot potato" voice. The parents deny the possibility of foreign body ingestion or trauma, and they report that they are delaying some of his vaccines.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Angioedema Males and females of any race or ethnicity 18 or older. The locations of the study will permit all racial and ethnic distribution in the study Must currently be on an ACE inhibitor Presenting with ACE induced angioedema within 12 hours after onset. This is to be documented in the source document and CRF All females of childbearing age must have a negative pregnancy test prior to administration of the study drug  Participation in another investigational study within 30 days prior to enrollment Patients who improve on conventional (standard of care) therapy Patients previously treated with ecallantide Hypersensitivity to ecallantide Pregnancy or breast feeding Other definable causes of angioedema (i.e., hereditary or acquired angioedema) Patients receiving C-1 inhibitor as prophylaxis Treatment requiring tranexamic acid, and epsilon-aminocaproic acid Receiving fresh frozen plasma within 3 days prior to enrollment